These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 15127424)

  • 21. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified.
    O'Mahony JF; Paulden M
    Value Health; 2014 Jul; 17(5):493-6. PubMed ID: 25128041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Local health care expenditure plans and their opportunity costs.
    Karlsberg Schaffer S; Sussex J; Devlin N; Walker A
    Health Policy; 2015 Sep; 119(9):1237-44. PubMed ID: 26251323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
    Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
    Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality, innovation, and value for money: NICE and the British National Health Service.
    Pearson SD; Rawlins MD
    JAMA; 2005 Nov; 294(20):2618-22. PubMed ID: 16304076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.
    Briggs A; Mihaylova B; Sculpher M; Hall A; Wolstenholme J; Simoons M; Deckers J; Ferrari R; Remme WJ; Bertrand M; Fox K;
    Heart; 2007 Sep; 93(9):1081-6. PubMed ID: 17135223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of national mandatory screening of all admissions to English National Health Service hospitals for meticillin-resistant Staphylococcus aureus: a mathematical modelling study.
    Robotham JV; Deeny SR; Fuller C; Hopkins S; Cookson B; Stone S
    Lancet Infect Dis; 2016 Mar; 16(3):348-56. PubMed ID: 26616206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decision making by NICE: examining the influences of evidence, process and context.
    Cerri KH; Knapp M; Fernández JL
    Health Econ Policy Law; 2014 Apr; 9(2):119-41. PubMed ID: 23688554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Societal Preferences for Interventions with the Same Efficiency: Assessment and Application to Decision Making.
    Shiroiwa T; Saito S; Shimozuma K; Kodama S; Noto S; Fukuda T
    Appl Health Econ Health Policy; 2016 Jun; 14(3):375-85. PubMed ID: 26940671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
    Bryan S; Williams I; McIver S
    Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The normative grounds for NICE decision-making: a narrative cross-disciplinary review of empirical studies.
    Charlton V
    Health Econ Policy Law; 2022 Oct; 17(4):444-470. PubMed ID: 35293306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence and values: paying for end-of-life drugs in the British NHS.
    Chalkidou K
    Health Econ Policy Law; 2012 Oct; 7(4):393-409. PubMed ID: 23079299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab for the treatment of rheumatoid arthritis.
    Bagust A; Boland A; Hockenhull J; Fleeman N; Greenhalgh J; Dundar Y; Proudlove C; Kennedy T; Moots R; Williamson P; Dickson R
    Health Technol Assess; 2009 Sep; 13 Suppl 2():23-9. PubMed ID: 19804686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
    Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative effectiveness review within the U.K.'s National Institute for Health and Clinical Excellence.
    Chalkidou K
    Issue Brief (Commonw Fund); 2009 Jul; 59():1-12. PubMed ID: 19639713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Should NICE's threshold range for cost per QALY be raised? No.
    Raftery J
    BMJ; 2009 Jan; 338():b185. PubMed ID: 19171562
    [No Abstract]   [Full Text] [Related]  

  • 37. Should NICE's threshold range for cost per QALY be raised? Yes.
    Towse A
    BMJ; 2009 Jan; 338():b181. PubMed ID: 19171561
    [No Abstract]   [Full Text] [Related]  

  • 38. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
    Hashem F; Calnan MW; Brown PR
    Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Public funding of new cancer drugs: Is NICE getting nastier?
    Mason AR; Drummond MF
    Eur J Cancer; 2009 May; 45(7):1188-1192. PubMed ID: 19138512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modifying NICE's Approach to Equity Weighting.
    Paulden M; McCabe C
    Pharmacoeconomics; 2021 Feb; 39(2):147-160. PubMed ID: 33517512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.